ALISO VIEJO, Calif., Oct. 18 /PRNewswire/ -- MicroVention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral and vascular peripheral diseases, announced today the recent launch of its HyperSoft Finishing Coil. The recently FDA-cleared HyperSoft Finishing Coil is an exceptionally soft, stretch-resistant helical platinum coil. When used in addition to traditional coil devices, the HyperSoft can result in increased volume filling and coil mass stability, thereby improving the durability of endovascular aneurysm repair.
"The addition of this technology complements our family of endovascular coiling products and provides the physicians the opportunity for a more thorough treatment in the endovascular occlusion of aneurysms," said Mike Kleine, President and CEO of MicroVention. "The softness and ease with which this coil can be delivered provides a greater packing potential and filling capacity and has been met with enthusiastic reviews in over 100 clinical cases."
The MicroVention HyperSoft Finishing Coil has a unique design allowing easier placement into small voids near the end of the procedure for improved filling in comparison to similarly sized competitive "finishing" coils. It also incorporates stretch-resistance, a feature that allows the coil to be more safely repositioned, if necessary. Competitive testing has shown that the HyperSoft Finishing Coil is the softest helical finishing coil on the market, and when coupled with MicroVention's delivery system, the physician has the capability to place the coil with virtually no microcatheter movement, even in tortuous anatomy.
Mary Lee Jensen, M.D., Director of Interventional Neuroradiology at the University of Virginia Hospital in Charlottesville, VA commented, "The HyperSoft has become my finishing coil of choice. This coil seeks space better than any of its competitors, resulting in very dense packing. MicroVention continues to deliver innovative products and the HyperSoft is no exception."
A cerebral aneurysm is a ballooning of a weakened region of a blood vessel. If left untreated, the aneurysm may continue to weaken until it ruptures and bleeds into the brain. Approximately 2 to 5 percent of the U.S. population is estimated to have cerebral aneurysms, although most go undetected. Over 150,000 cerebral aneurysm patients are treated annually worldwide, and an increasing number of these procedures are being performed endovascularly.
About MicroVention, Inc.
MicroVention, Inc. (www.microvention.com) is a privately held medical device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of cerebral and peripheral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System to treat cerebral aneurysms. MicroVention sells its products through its direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors in other countries.
Michael Kleine, President, CEO Matt Clawson (Media)
William Hughes, Vice President, CFO Allen & Caron, Inc.
Ph. 949-461-3314 Ph. 949-474-4300
Fx. 949-461-3329 Fx. 949-474-4330
CONTACT: Michael Kleine, President, CEO, or William Hughes, VicePresident, CFO, both of MicroVention, Inc., +1-949-461-3314, or fax,+1-949-461-3329; or Media, Matt Clawson of Allen & Caron, Inc.,+1-949-474-4300, or fax, +1-949-474-4330, for MicroVention, Inc.